Extended Data Fig. 6: SPR based analysis of serum antibodies to purified proteins of SARS-CoV-2 proteome.
From: SARS-CoV-2 immune repertoire in MIS-C and pediatric COVID-19
(a) Serial dilutions of first time-point drawn serum sample from each the controls and SARS-CoV-2 infected children were analyzed for antibody binding to 28 purified SARS-CoV-2 proteins and prefusion spike proteins from other coronaviruses or RSV prefusion-F or H1N1 influenza HA. Rest of the SPR data are shown in Fig. 3. The samples are coded by groups: grey, Mild/moderate Control (n = 9); black, Severe control (n = 5); orange, Mild/moderate COVID-19 (n = 20); red, Severe COVID-19 (n = 15); cyan, Mild/moderate MIS-C (n = 8); blue, Severe MIS-C (n = 17). Total antibody binding shown is observed maximum RU for 10-fold diluted serum sample. (b) SPR based analysis of SARS-CoV-2-seropositive children to SARS-CoV-2 prefusion spike, Flu-HA and RSV-F. Serum sample from hospitalized controls (n = 7; black) and SARS-CoV-2 infected seropositive children (20 COVID-19, shown in red or 10 MIS-C, shown in blue) were analyzed for antibody binding to purified SARS-CoV-2 prefusion spike protein or RSV prefusion-F or H1N1 influenza HA. Total antibody binding shown is observed maximum RU for 10-fold diluted serum sample. Differences among groups were performed using R. The tests were two-sided using Tukey multiple group comparisons to reduce Type 1 error. The differences were considered statistically significant with a 95% confidence interval when the p value was less than 0.05. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001).
